<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675801</url>
  </required_header>
  <id_info>
    <org_study_id>SAFE</org_study_id>
    <nct_id>NCT04675801</nct_id>
  </id_info>
  <brief_title>SAfety and EFficacy of Bridging Antithrombotic Therapy During Elective Non-cardiac Surgery</brief_title>
  <acronym>SAFE</acronym>
  <official_title>Safety and Efficacy of Bridging Antithrombotic Therapy During Elective Non-cardiac Surgery for Coronary Artery Disease Patients Treated With Oral Antiplatelet Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with coronary artery disease, especially after PCI, require long-term oral&#xD;
      antiplatelet therapy. However, this patient population may inevitably require non-cardiac&#xD;
      surgery for a variety of conditions. In order to avoid the occurrence of bleeding events,&#xD;
      oral antiplatelet agents are usually discontinued before non-cardiac surgery in patients with&#xD;
      coronary artery disease, which may increase the incidence of ischemic events. Therefore, it&#xD;
      is important to provide patients with the optimal perioperative antithrombotic treatment to&#xD;
      balance the risk of bleeding and ischemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>Perioperative period</time_frame>
    <description>A composite of all-cause death, non-fatal myocardial infarction, or non-fatal stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIMI major or minor bleeding</measure>
    <time_frame>Perioperative period</time_frame>
    <description>A composite of major or minor bleeding events as defined by the TIMI bleeding criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net adverse clinical events</measure>
    <time_frame>Perioperative period</time_frame>
    <description>A composite of major adverse cardiovascular events and TIMI major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net adverse clinical events</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>A composite of major adverse cardiovascular events and TIMI major or minor bleeding</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bridging therapy with LMWH (n=475)</arm_group_label>
    <description>Bridging therapy with LMWH was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bridging therapy with tirofiban (n=475)</arm_group_label>
    <description>Bridging therapy with tirofiban was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Coronary artery disease patients treated with oral antiplatelet therapy are planned to&#xD;
        undergo non-cardiac surgery with high or extremely high surgical bleeding risk&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years or over&#xD;
&#xD;
          2. Established coronary artery disease being treated with oral antiplatelet therapy&#xD;
&#xD;
          3. Non-cardiac surgery is planned and bridging antithrombotic therapy is considered&#xD;
             necessary&#xD;
&#xD;
          4. Agree to participate in the study and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. According to the consensus of Chinese experts on antiplatelet therapy in 2013, the&#xD;
             surgical bleeding risk is low or extremely low&#xD;
&#xD;
          2. Requiring emergency non-cardiac surgery within 24 hours after admission&#xD;
&#xD;
          3. Currently being bleeding&#xD;
&#xD;
          4. Moderate or severe ischemic stroke or spontaneous intracranial hemorrhage in the past&#xD;
             6 months or traumatic intracranial hemorrhage in the past 1 year&#xD;
&#xD;
          5. Intracranial diseases or hemorrhagic diathesis&#xD;
&#xD;
          6. Contraindications for LMWH or GP IIb/IIIa receptor antagonists&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoli Liu, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoli Liu, PhD, MD</last_name>
    <phone>8613581633895</phone>
    <email>liuxl9881@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoli Liu, PhD, MD</last_name>
      <phone>8613581633895</phone>
      <email>liuxl9881@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaoteng Ma, PhD, MD</last_name>
      <phone>8618810616459</phone>
      <email>maxiaotengai@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaoli Liu, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yujie Zhou</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Bridging antithrombotic therapy</keyword>
  <keyword>Non-cardiac surgery</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

